Sanofi Calms France's Fears Over COVID-19 Vaccine Access
CEO Hudson Clarifies 'US First' Comments
Paul Hudson has been at the helm of Sanofi for just nine months, but for the last few days his comments about which country will be first in line for the firm's coronavirus vaccines will have reminded him that the Gallic culture runs deep.
You may also be interested in...
Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.
Sanofi’s €610m investment helps row to be forgotten – though Macron will ‘place bets’ on several COVID-19 vaccines, not just France’s homegrown candidate.
An official announcement is expected within weeks, as competition between US and China stokes fears of 'vaccine nationalism'.